Parcell Laboratories

Parcell Laboratories is a regenerative medicine company that develops and markets stem cell-based products for the orthopedic and wound care markets. The company's core innovation is the E-CEL (Endothelial-like Cell) technology platform, which harnesses a specific population of cells from the human umbilical cord to promote vascularization and tissue healing. Their flagship product, A-CEL, is an amniotic-derived cellular matrix used as a bone graft substitute in spinal fusion and other complex orthopedic procedures. By utilizing neonatal-derived cells, Parcell aims to provide superior regenerative outcomes compared to adult stem cell treatments. In 2017, Parcell Laboratories was acquired by Medline Industries, a major healthcare manufacturer and distributor, to expand its presence in the advanced wound care and regenerative medicine sectors.